Transforming growth factor β receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk

Gynecologic Oncology

Volumn 97, Issue 2, 2005, Pages 543-549

  Spillman, Monique A ^a   Schildkraut, Joellen M ^a   Halabi, Susan ^a   Moorman, Patricia ^a   Calingaert, Brian ^a   Bentley, Rex C ^a   Marks, Jeffrey R ^a   Murphy, Susan ^a   Berchuck, Andrew ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

6A allele; Case control study; Ovarian cancer; TGF RI

Indexed keywords

ALANINE DERIVATIVE; POLYALANINE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RACE DIFFERENCE;

EID: 18144364326     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.01.025     Document Type: Article

References (19)

1. M. Sporn TGF-β: 20 years and counting Microbes Infect. 1 1999 1251 1253
2. J. Massague How cells read TGF-β signals Nat. Rev., Mol. Biol. 1 2000 169 178
3. Y. Shi, and J. Massague Mechanisms of TGF-β signaling from cell membrane to the nucleus Cell 113 2003 685 700
4. M. Rendi, N. Suh, W. Lamph, S. Krajewski, J. Reed, and R. Heyman The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer Cancer Res. 15 64 2004 (May) 3566 3571
5. S.-J. Kim, Y.-H. Im, S.D. Markowitz, and Y.-J. Bang Molecular mechanisms of inactivation of TGF-β receptors during carcinogenesis Cytokine Growth Factor Rev. 11 2000 159 168
6. E. del Re, J.L. Babitt, A. Pirani, A.L. Schneyer, and H.Y. Lin In the absence of type III receptor, the transforming growth factor (TGF)-β type II-B receptor requires the type I receptor to bind TGF-beta2 J. Biol. Chem. 279 2004 22765 22772
7. A. Bandyopadhyay, Y. Zhu, S.N. Malik, J. Kreisberg, M.G. Brattain, and E.A. Sprague Extracellular domain of TGFβ type III receptor inhibits angiogenesis and tumor growth in human cancer cells Oncogene 21 2002 3541 3551
8. B. Pasche, P. Kalachana, K. Nafa, J. Satagopan, Y.-G. Chen, and R.S. Lo TBR-1(6A) is a candidate tumor susceptibility allele Cancer Res. 59 1999 5678 5682
9. S.W. Baxter, D.Y.H. Choong, D.M. Eccles, and I.G. Campbell Transforming growth factor β receptor 1 polyalanine polymorphism and exon 5 mutation analysis in breast and ovarian cancer Cancer Epidemiol. Biomarkers Prev. 11 2002 211 214
10. V.G. Kaklamani, N. Hou, Y. Bian, J. Reich, K. Offit, and L.S. Michel TGFβR1*6A and cancer risk: a meta-analysis of seven cancer-control studies J. Clin. Oncol. 21 2003 3236 3243
11. W.S. Samowitz, K. Curtin, M.F. Leppert, and M.L. Slattery Uncommon TGFβR1 allele is not associated with increased susceptibility to colon cancer Genes Chromosomes Cancer 32 2001 381 383
12. B. Pasche, Y. Luo, P.H. Rao, S.D. Nimer, E. Dmitrovsky, and P. Caron Type I transforming growth factor B receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract Cancer Res. 58 1998 2727 2732
13. R. Lai Association between TGFβR1*6A and cancer: is there any evidence? J. Clin. Oncol. 22 2004 2754
14. B. Pasche, V.G. Kaklamani, N. Hou, T. Young, A. Rademaker, and P. Peterlongo TGFβR1*6A and cancer: a meta-analysis of 12 case-control studies J. Clin. Oncol. 22 2004 756 758
15. R.M. Wenham, J.M. Schildkraut, K. McLean, B. Calingaert, R.C. Bentley, and J. Marks Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer Clin. Cancer Res. 9 2003 4396 4403
16. J.M. Lancaster, R.M. Wenham, S. Halabi, B. Calingaert, J.R. Marks, and P.G. Moorman No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina Cancer Epidemiol. Biomarkers Prev. 12 2003 226 227
17. A. Berchuck, J. Schildkraut, R. Wenham, B. Calingaert, S. Ali, and A. Henriott Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers Cancer Epidemiol. Biomarkers Prev. 13 2004 2141 2147
18. A.-M. Stefanovska, G. Efremov, and A.J. Dimovski TBR-I(6A) Polymorphism is not a tumor susceptibility allele in Macedonian colorectal cancer patients Cancer Res. 61 2001 8351
19. A.A.G. van Tilborg, A. de Vries, and E.C. Zwarthoff The chromosome 9q genes TGFβRI, TSCI, and ZNF189 are rarely mutated in bladder cancer J. Pathol. 194 2001 76 80